Last reviewed · How we verify
Hydrochlorothiazide and furosemide
At a glance
| Generic name | Hydrochlorothiazide and furosemide |
|---|---|
| Sponsor | Corporacion Parc Tauli |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Protocol of Diuretics Use in Congestive Therapy in Heart Failure (PHASE4)
- Diuretics and Volume Overload in Early CKD (PHASE4)
- The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure (PHASE3)
- EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU) (NA)
- Influence of Lung Ultrasonography on the Prognosis and Postoperative Outcomes in Cardiac Surgical Patients (NA)
- Phototoxicity of Frequently Prescribed Medicines (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydrochlorothiazide and furosemide CI brief — competitive landscape report
- Hydrochlorothiazide and furosemide updates RSS · CI watch RSS
- Corporacion Parc Tauli portfolio CI